SG/CALL/BRISTOL-MYERS SQUIBB/70/0.1/21.06.24 | Market Closed - Deutsche Boerse AG 01:13:36 01/06/2024 am IST | ||
| 0.001 EUR | -.--% |
|
| 6 months | -93.33% | ||
| Current year | -94.12% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 0.001 | -.--% |
| 30/24/30 | 0.001 | -.--% |
| 29/24/29 | 0.001 | -.--% |
| 28/24/28 | 0.001 | -.--% |
| 27/24/27 | 0.001 | -.--% |
Delayed Quote Deutsche Boerse AG
Last update May 01, 2024 at 01:13 am IST
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SQ4FE7 |
| ISIN | DE000SQ4FE73 |
| Date issued | 16/11/2022 |
| Strike | 70 $ |
| Maturity | 21/06/2024 (20 Days) |
| Parity | 10 : 1 |
| Emission price | 1.43 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.68 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.019 € |
| Spread % | 95.00% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.09
USD
Average target price
53.19
USD
Spread / Average Target
+29.46%
- Stock Market
- Warrants
- Warrant
